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Abstract
Background: Breast cancer is a potentially fatal malignancy in females despite the improvement in therapeutic
techniques. The identification of novel molecular signatures is needed for earlier detection, monitoring effects of
treatment, and predicting prognosis. We have previously used microarray analysis to identify differentially expressed
genes in aggressive breast tumors. The purpose of the present study was to investigate the prognostic value of the
candidate biomarkers CCNB2, ASPM, CDCA7, KIAA0101, and SLC27A2 in breast cancer.
Methods: The expression levels and subcellular localization of the CCNB2, ASPM, CDCA7, KIAA0101, and SLC27A2
proteins were measured using immunohistochemistry (IHC) on a panel of 80 primary invasive breast tumors.
Furthermore, the mRNA levels of CCNB2, KIAA0101, and SLC27A2 were subsequently examined by qRT-PCR to
validate IHC results. Patient disease-specific survival (DSS) was evaluated in correlation to protein levels using the
Kaplan-Meier method. Multivariate Cox regression analysis was used to determine the impact of aberrant protein
expression of the candidate biomarkers on patient DSS and to estimate the hazard ratio at 8-year follow-up.
Results: Elevated cytoplasmic CCNB2 protein levels were strongly associated with short-term disease-specific
survival of breast cancer patients (≤ 8 years; P<0.001) and with histological tumor type (P= 0.04). However, no
association with other clinicopathological parameters was observed. Multivariate Cox regression analysis specified
that CCNB2 protein expression is an independent prognostic marker of DSS in breast cancer. The predictive ability
of several classical clinicopathological parameters was improved when used in conjunction with CCNB2 protein
expression (C-index = 0.795) in comparison with a model without CCNB2 expression (C-index = 0.698). The protein
levels of ASPM, CDCA7, KIAA0101, and SLC27A2 did not correlate with any clinicopathological parameter and had
no influence on DSS. However, a significant correlation between the expression of the CCNB2 and ASPM proteins
was detected (P = 0.03).
Conclusion: These findings suggest that cytoplasmic CCNB2 may function as an oncogene and could serve as a
potential biomarker of unfavorable prognosis over short-term follow-up in breast cancer.
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Worldwide, breast cancer is responsible for more than half
a million deaths each year, but the ability to predict clinical
outcome of the disease is still limited [1]. Breast cancer is
a complex multi-gene disease involving the activation of
oncogenes, loss of tumor suppressor genes, and disruption
of vital cell-signaling pathways responsible for cell sur-
vival, growth, differentiation, and apoptosis. In recent
years, the cellular and molecular characterization of breast
cancer has catalyzed a shift toward the development of
improved diagnosis and treatment of this disease [2,3]. To
improve long-term survival rates and quality of life, several
treatment regimens are currently available, including sur-
gery combined with adjuvant therapy. Furthermore, sev-
eral clinicopathological factors are also used to stratify
patients into groups with different prognoses and to pre-
dict their response to adjuvant systemic therapies, includ-
ing histological tumor grade, stage, size, age at diagnosis,
axillary lymph node status, human epidermal growth fac-
tor receptor 2 (HER2/neu) status, steroid hormone recep-
tor expression, and vascular invasion [4,5]. However,
despite improvements in the treatment of breast cancer, it
remains the second most common cause of death in
women after lung cancer. Moreover, breast cancer inci-
dence has risen steadily in recent years and many patients
are exposed to ineffective therapies, as well as, to unneces-
sary treatment-related toxicity [6]. Therefore, there is in-
tense focus on the development of improved treatment for
breast cancer, especially targeted therapies.
Recently, we performed a detailed analysis of copy
number and gene expression in 97 primary invasive dip-
loid breast tumors [7]. We identified molecular gene sig-
natures in aggressive tumors that resulted in different
clinical outcomes. In the present investigation, five genes
(CCNB2, CDCA7, ASPM, KIAA0101, and SLC27A2)
were selected from these gene signatures based on their
significantly deregulated gene expression according to
short-term disease-specific survival, triple-negative sta-
tus, and/or stratified according to histological grade as
defined by Bloom, Richardson, Elston/Ellis (BRE) grad-
ing system [8]. In addition, CCNB2, ASPM, KIAA0101,
and CDCA7 are known to be involved in DNA repair,
DNA replication, and cell cycle arrest [9-13], whereas
SLC27A2 plays a role in fatty acid transport [14]. We
then further analyzed their protein levels and subcellular
localization in relation to patient clinical outcome as
well as with clinicopathological features in an independ-
ent cohort of 80 primary invasive breast tumors.
Methods
Tumor specimens
Primary invasive tumors were obtained from 80 patients
who had undergone surgery from the 1990 to 2006 at
Sahlgrenska University Hospital, Gothenburg, Sweden.
Formalin-fixed, paraffin-embedded tissues (FFPE) and
fresh-frozen primary invasive breast carcinomas were
obtained from the Departments of Pathology and Oncology
at Sahlgrenska University Hospital in accordance with the
Declaration of Helsinki and approved by the Medical
Faculty Research Ethics Committee (Gothenburg, Sweden).
The clinical and morphologic characteristics of the tumors
are summarized in Table 1. To examine potential variations
in protein expression of candidate biomarkers, the tumors
were stratified according to disease-specific survival (DSS)
with 8-year censoring, and histological grade as defined by
Bloom, Richardson, Elston/Ellis (BRE) grading system [8].
Immunohistochemistry (IHC)
Antibodies corresponding to CCNB2, CDCA7, KIAA0101,
SLC27A2, and ASPM were optimized using 12 independ-
ent primary invasive breast tumors with different stage
I-III as controls. Four micrometer FFPE sections were ap-
plied onto positively charged slides (FLEX IHC microscope
slides, Dako, Sweden) and subsequently immunostained
with rabbit anti-CCNB2 (Sigma-Aldrich, Stockholm,
Sweden, HPA008873, 1:100 dilution), rabbit anti-CDCA7
(Sigma-Aldrich, HPA005565, 1:50 dilution), rabbit anti-
SLC27A2 (Sigma-Aldrich, HPA026089, 1:50 dilution),
mouse anti-KIAA0101 (Abnova, Stockholm, Sweden,
H00009768-M01, 1:200 dilution), and rabbit anti-ASPM
(Novus Biologicals, England, UK, 25970002, 1:1100 dilu-
tion) to determine protein expression levels and subcel-
lular localization of the corresponding proteins in breast
tumors. The FFPE sections were processed with the Dako
EnVision™ FLEX antigen retrieval EDTA buffer (pH 9)
for 20 minutes at 97°C using DAKO PT Link module
(PT Link, Dakocytomation, Denmark) according to the
manufacturer's instructions. The IHC procedure was per-
formed using DAKO stainer (DAKO Auotstainer plus,
Dakocytomation, Denmark) following the manufacturer's
instructions. Antibody staining was evaluated by a single
pathologist (AK). At the time of examination, the path-
ologist was blinded as to the diagnosis and other clinico-
pathological data. Immunoreactivity was defined as
negative with a score of 0 (no staining in any cells or very
weak cytoplasmic or nucleus staining in less than 10% of
the invasive tumor cells). Positive immunoreactivity was
defined as 1+ (weak to moderate staining in more than
10% of the invasive tumor cells) or 2+ (moderate to
strong staining in more than 10% of the invasive tumor
cells). Areas with intraductal carcinoma were excluded
from the evaluation.
Fluorescence in situ hybridization (FISH)
To assess HER2/neu gene status in the 67/80 available fresh-
frozen tumor samples, fluorescence in situ hybridization was
performed. A bacterial artificial chromosome (BAC)
clone covering the HER2/neu locus (RP11-94L15) was
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CA, USA, http://bacpac.chori.org/) and used as a FISH
probe. FISH was performed on tumor touch-prints pre-
pared from fresh-frozen tumors as described elsewhere
[15]. The analysis was performed on a Leica DMRA2
fluorescence microscope (Leica, Stockholm, Sweden)
equipped with an ORCA Hamamatsu charged-couple
devices camera (Hamamatsu Corporation, Stockholm,
Sweden). Scoring of HER2/neu hybridization signals was
carried out in each tumor specimen by counting the
number of signals in at least 100 nuclei. Specimens were
scored as either positive (1) when HER2/neu gene ampli-
fications were detected in more than 10% of the analyzed
cells or negative (0) in all other cases.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from fresh-frozen tumor speci-
mens using TRIzol reagent (Life Technologies, Stockholm,
Sweden) and the Qiagen RNeasy mini kit (Qiagen,
Stockholm, Sweden) according to the manufacturer's
instructions, followed by treatment with RNase-free
DNase (Ambion, Texas, USA). One microgram total
RNA was converted to cDNA using random hexamers
and Superscript III (Life Technologies) according to
standard procedures. Validation of the IHC and FISH
results was performed using qRT-PCR with TaqMan Gene
Expression Assays (Life Technologies) for CCNB2 (Hs-
00270424_m1), KIAA0101 (Hs00207134_m1), SLC27-
A2 (Hs00186324_m1), and HER2/neu (Hs01001580_m1)
Table 1 Clinicopathological characteristics of 80 invasive breast cancer patients
Characteristics pBRE I-II Survivors ≥8years
(n= 21)
pBRE III Survivors ≥8years
(n=19)
pBRE I-II Survivors < 8 years
(n= 20)
pBRE III Survivors <8 years
(n=20)
Mean age (y) 58 (39–72) 52 (27–7) 55 (39–71) 53 (33–72)
Histologic type
Ductal 15 (71) 18 (95) 15 (75) 16 (80)
Lobular 2 (10) 1 (5) 4 (20) 3 (15)
Ductal+ lobular 0 (0) 0 (0) 1 (5) 0 (0)
Other 3 (14) 0 (0) 0 (0) 1 (5)
Not available 1 (5) 0 (0) 0 (0) 0 (0)
Pathologic tumor size
(mm)
pT1 (0–20) 2 (9) 6 (32) 3 (15) 5 (25)
pT2 (>20-50) 18 (86) 9 (47) 16 (80) 13 (65)
pT3 (>50) 1 (5) 4 (21) 1 (5) 2 (10)
pT4 0 (0) 0 (0) 0 (0) 0 (0)
BRE grade
I-II 21 (100) 20 (100)
III 19 (100) 20 (100)
No. of axillary lymph
nodes
0 7 (33) 7 (37) 7 (35) 7 (35)
1-3 5 (24) 7 (37) 6 (30) 6 (30)
≥4 9 (43) 5 (26) 7 (35) 7 (35)
Surgery
Lumpectomy 9 (43) 6 (32) 9 (45) 6 (30)
Mastectomy 12 (57) 13 (68) 11 (55) 14 (70)
ER/PR status
Negative 11 (52) 8 (42) 13 (65) 7 (35)
Positive 9 (43) 11 (58) 7 (35) 13 (65)
Not available 1 (5)
HER2/neu status
Positive 7 (33) 8 (42) 8 (40) 3 (15)
Negative 11 (52) 10 (53) 11 (55) 9 (45)
Not available 3 (15) 1 (5) 1 (5) 8 (40)
(N)= No. of patients (%).
BRE, Bloom, Richardson, Elston/Ellis; ER/PR: Estrogen/progesterone receptor.
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IHC and FISH analyses. The qRT-PCR reactions for each
sample were performed in duplicate in independent
experiments.
The HPRT1 gene (Hs02800695_m1) was initially selected
as an endogenous control because it exhibited low variance
in mRNA expression between samples (data not shown).
The qRT-PCR reactions (10 μlt o t a l )i n c l u d e d2μlo f
cDNA template, 2x TaqMan Universal PCR Master Mix
(ABI, Foster City, USA), and 1x FAM labeled gene-specific
assay. All qRT-PCR reactions were performed in 384-well
plates using the ABI PRISM 7900HT Sequence Detection
System (ABI, Foster City, USA) with an initiation step at
95°C for 10 minutes, followed by 40 cycles at 95°C for 15
seconds and at 60°C for 1 minute. For each assay, a tem-
plate dilution standard curve (5-fold range) was recorded.
Genomic DNA and no-template samples were included as
controls. Relative gene expression levels were calculated
with the relative standard curve method using CTvalues of
the analyzed genes normalized with HPRT1 [16].
Statistical analysis
Protein expression was examined in relation to DSS using
the Kaplan-Meier method and was compared with the
log-rank test. Univariate and multivariate models using
proportional hazards regression were applied as an ex-
ploratory tool to assess the effect of the selected markers
on DSS. Multivariate models were employed to adjust for
possible confounding effect to classical clinicopathological
features including tumor grade, tumor size, axillary lymph
node status, HER2/neu, and estrogen receptor (ER)/ pro-
gesterone receptor (PR) status. The predictive power of
the models was assessed as time dependent Area Under
the Receiver Operatic Characteristic Curves (AUC(t)) and
summarized by the concordance index (C-index) [17].
The C-index varies between 0.5 (no predictive power) and
1 (perfect prediction). Associations were evaluated by
using the χ2-test or t-test, where appropriate. The prob-
ability (P) values were two-sided and considered statisti-
cally significant if P <0.05. All statistical manipulations
were performed using the SPSS version 20.0 and R 2.14.0
statistical software.
Results
Clinicopathological characteristics
Eighty FFPE specimens from primary invasive breast
tumors were initially collected for use in the present
study. Due to loss of biopsy cores, insufficient tumor
cells present in the cores or affluence of necrotic tissue,
72/80 FFPE specimens were evaluated for CCNB2,
KIAA0101, SLC27A2, ASPM, and CDCA7 immunos-
taining. The mean age of the patients was 54.5 years
with a range of 27–73 years. In total, 65% of the patients
were over 50 years of age. Tumor size distribution was
20% for ≤ 2 cm, 70% for 2–5 cm, and 10% for >5 cm.
Among the patients, 35% were axillary lymph node-
negative and 65% were axillary lymph node-positive.
Lymph node-positive patients were further subdivided
into two sub-groups based on the number of node me-
tastases, 1–3 (46%) and≥ 4 (54%). The tumors were
stratified according to histological grade as defined by
Bloom, Richardson, Elston/Ellis (BRE) grading system
[8] identifying 51% of patients with grade I and II
tumors, and 49% with grade III tumors. Thirty-nine per-
cent of the patients (26/67 available fresh-frozen sam-
ples) were HER2/neu positive and 61% were HER2/neu
negative at the DNA level. The cohort consisted of long-
term survivors (46%, ≥8-year survival) and short-term
survivors (54%, <8-year survival). Further detailed clin-
ical information is presented in Table 1.
Increased cytoplasmic expression of CCNB2 is associated
with unfavorable prognosis
The cytoplasmic localization of the CCNB2 protein was
detected in 74% of the samples, of which 92% of tumors
from short-term survivors were CCNB2 positive (Figure 1).
The univariate Cox proportional hazards regression ana-
lysis revealed that cytoplasmic CCNB2 expression was sig-
nificantly associated with DSS (HR, 6.1; 95% CI: 2–20;
Table 2). The effect of CCNB2 protein expression on pa-
tient DSS was evaluated by Kaplan-Meier analysis. As seen
in Figure 2, over-expression of the CCNB2 protein had an
adverse effect on survival rates (P=0. 00 1) .
Approximately 69% of the 72 samples were positive for
ASPM staining, displaying mainly granular nuclear stain-
ing. The expression of ASPM was similar regardless
of the survival group. The CDCA7 protein was strongly
expressed in the cell nucleus in all samples. The KIAA0101
protein was equally expressed in the cell nucleus in 79% of
the analyzed specimens. Thirty percent of the long-term
survivors and 20% of the short-term survivors expressed
SLC27A2 in the cell cytoplasm (Figure 3). Furthermore,
Kaplan-Meier analysis of CDCA7, ASPM, KIAA0101, and
SLC27A2 were also performed. No differences in DSS in
relation to protein expression were seen (data not shown).
CCNB2 is an independent prognostic marker for breast
cancer
For statistical analysis, the tumors were stratified into four
groups according to CCNB2 protein levels and DSS status.
As seen in Table 2, CCNB2 protein levels were signifi-
cantly correlated with histological tumor type (P=0.04),
but no association of CCNB2 protein expression with the
clinicopathological characteristics age, histological grade,
nodal status, tumor size, ER/PR or HER2/neu status were
identified. However, in the two survival groups a signifi-
cant correlation between CCNB2 and ASPM protein ex-
pression was found (P=0.03). Furthermore, histological
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tus HER2/neu status, and cytoplasmic CCNB2 expression
were included in multivariate survival analysis which
showed that CCNB2 over-expression was an independent
prognostic marker for disease specific survival in breast
cancer (P=0. 00 3 ;95 %CI:2 –20; Table 3). As presented in
Figure 4, we further calculated the C-index by using three
models (CCNB2 with clinicopathological parameters and
both models alone) to evaluate the predictive power of
CCNB2. The C-index for CCNB2 alone was 0.662 with
enhanced predictive accuracy over time. Furthermore, the
predictive power for CCNB2 protein expression was
higher together with the analyzed clinicopathological para-
meters (C-index=0.795) than with the clinicopathological
parameters alone (C-index=0.698) for predicting breast
cancer specific-survival within 8-years follow-up. The dif-
ference between the CCNB2 and clinicopathological mod-
els was slightly less convincing. In addition, we noted that
the predictive accuracy for the clinicopathological model
without CCNB2 displays a considerable decreasing ten-
dency over time.
Quantitative real-time PCR analysis
Quantitative RT-PCR was performed to measure mRNA
levels for the CCNB2, KIAA0101, SLC27A2,a n dH E R 2 / neu
genes and to validate the IHC and FISH results. We
observed a positive association between the mRNA and
protein levels of CCNB2 (t-test, P<0.001; Figure 5). The
overall concordance between immunohistochemistry and
qRT-PCR for CCNB2 was 94% (58/62). The four discordant
cases showed CCNB2positivity, but low mRNA expression.
A significant association between the gene amplification
and mRNA levels of HER2/neu was also detected (t-test,
Figure 1 Immunohistochemical detection of CCNB2 expression
in primary invasive breast tumors.
Table 2 Cytoplasmic CCNB2 staining, clinicopathological
characteristics and univariate Cox Regression analysis in
80 invasive breast cancer patients
Cytoplasmic CCNB2 expression
Characteristics Negative Positive P* HR 95% CI P ¤
Age (years) 0.79 1.5 0.8-2.9 0.2
27-50 6 (24) 19 (76)
>50 13 (28) 34 (72)
Histologic type 0.04 0.8 0.4-1.5 0.5
Ductal 17 (29) 41 (71)
Lobular 0 (0) 8 (100)
Ductal+ lobular 1(100) 0 (0)
Other 0 (0) 4 (100)
Tumor size (mm) 0.88 1.0 1.0-1.0 1.0
pT1 (0–20) 3 (25) 9 (75)
pT2 (>20-50) 14 (27) 38 (73)
pT3 (>50) 2 (25) 6 (75)
BRE grade 0.99 1.1 0.8-1.5 0.5
I-II 10 (28) 26 (72)
III 9 (25 ) 27 (75)
Axillary lymph node status 0.90 1.0 0.5-2.0 1.0
Negative 6 (25) 18 (75)
Positive 13 (27) 35 (73)
No. of axillary lymph nodes 0.34 1.0 0.7-1.4 0.8
1-3 4 (19) 17 (81)
≥4 9 (33) 18 (67)
ER/PR status 0.40 1.1 0.6-2.1 0.8
Negative 11 (32) 23 (68)
Positive 8 (21) 30 (79)
HER2/neu status 0.9 0.7 0.3-1.5 0.4
Positive 7 (32) 15 (68)
Negative 10 (27) 27 (73)
ASPM 0.03 0.9 0.5-20 0.9
Negative 10 (45) 12 (55)
Positive 24 (37) 41 (63)
KIAA0101 0.70 1.1 0.5-2.3 0.8
Negative 16 (48) 17 (52)
Positive 3 (8) 36 (92)
SLC27A2 0.08 0.6 0.3-1.3 0.2
Negative 11 (20) 43 (80)
Positive 8 (44) 10 (56)
CCNB2 19 (26) 53 (74) 0.004 6.1 2.0-20 0.003
P-value determined by chi-square test. * P-value of the correlation between
CCNB-2 expression and clinicopatholigical parameters. ¤ P-value of hazard
ratio (HR). BRE, Bloom, Richardson, Elston/Ellis; CI, confidence interval. All
parameters were coded as 0 (negative) and 1 (positive) except as noted.
Pathologic tumor size was coded as 1 (0-20mm), 2 (>20-50mm) and 3
(>50mm). Histologic type was coded as 1 (ductal), 2 (lobular ductal),
3 (ductal and lobular) and 4 (other). (N) = No. of patients (%).
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Figure 2 Kaplan-Meier curves illustrating the effect of CCNB2
expression on disease specific survival in breast cancer. Dashed
line represents patients whose tumors over-expressed CCNB2 and solid
line represents patients whose tumors did not. The p-values for the
difference between the curves were calculated using log-rank test.
Figure 3 Immunohistochemical detection of ASPM (A), CDCA7 (B), KIAA0101(C) and SLC27A2 (D) protein levels in primary invasive
breast tumors.
Table 3 Multivariate Cox regression analysis on
disease-specific survival in 80 invasive breast cancer
patients
Disease specific survival
Characteristics β SE HR 95% CI P-value*
BRE grade 0.14 0.17 1.16 0.83-1.61 0.39
HER2/neu status 0.18 0.40 0.83 0.39-1.80 0.64
Axillary lymph node status 0.03 0.35 1.03 0.53-2.04 0.64
Pathologic tumor size 0.001 0.01 0.10 0.98-1.02 0.97
ER/PR status 0.03 0.35 0.99 0.49-1.95 0.94
CCNB2 1.82 0.61 6.14 1.87-20.1 0.003
* Determined by chi-square test.
β: Regression coefficient; SE: standard error of β; HR: hazard ratio; and CI:
confidence interval. BRE: Bloom, Richardson, Elston/ Ellis; ER/PR: Estrogen/
progesterone receptor. Coding of characteristics: BRE, HER2/neu status, Axillary
lymph node status, ER/PR and CCNB2 were coded as 0 (negative) and 1
(positive) respectively. Pathologic tumor size was coded as 1
(0-20mm), 2 (>20-50mm), and 3 (>50mm).
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HER2/neu DNA copy number and mRNA expression was
94% (58/62). Three of the discordant samples revealed nor-
mal DNA copy numbers, but were highly expressed on the
mRNA level. High KIAA0101 and SLC27A2 mRNA levels
were detected in 92% and 83% of the samples, respectively.
However, there was no relation between KIAA0101 and
SLC27A2 mRNA levels and their corresponding protein
levels (t-test, P=0 .7 76andP=0.973 respectively, Figure 5),
indicating the expression of KIAA0101 and SLC27A2
mRNA levels appear to be independent of the presence of
protein.
Discussion
Despite the use of combination therapies including sur-
gery and other systemic treatments (radiotherapy, endo-
crine therapy, and anticancer agents), many breast
cancer patients will ultimately develop metastatic dis-
ease, which remains to be essentially incurable. There-
fore, identification of novel prognostic and predictive
biomarkers for breast tumors is needed and remains a
long awaited priority to enhance individualized treatment.
Recently, we identified molecular gene signatures asso-
ciated with aggressive breast cancer [7]. Here, we present
a validation of the prognostic role of five selected candi-
date biomarkers (CCNB2, ASPM, KIAA0101, CDCA7,
and SLC27A2) included in these gene signatures using an
independent breast cancer cohort.
In the present study, elevated CCNB2 protein levels
were significantly associated with shorter DSS. Promin-
ently, the HR of patients whose tumors were CCNB2-
positive was 6.1 corresponding to a dramatic increase in
probability of mortality compared with patients whose
tumors had very little or no expression.
It is well-known that different cyclins regulate the
eukaryotic cell cycle in association with cyclin dependant
kinases (cdks) at specific points of the mitotic cycle. Cell
cycle progression follows periodic alternations in the
protein levels of cyclins, D, E, A and B. Deregulated
levels of cyclins have been frequently observed in breast
cancer [18]. Elevated levels of cyclin E was significantly
correlated with DSS in patients with breast cancer [19].
Amplification and/or overexpression of cyclin D1 have
been correlated to poor prognosis in breast cancer
patients [20]. The Cyclin A upregulation was reported to
be associated with increased risk of recurrence among
breast cancer patients with node negative tumors [21].
The CCNB2 gene is a member of the B-type cyclin fam-
ily, including cyclin B1 and B2. It is involved in the G2-
M transition in eukaryotes by activating CDC2 kinase
and its inhibition induces cell cycle arrest [9,22,23]. In
agreement with a crucial role in cell growth, numerous
studies detected overexpression of CCNB2 in human
tumors, including lung, colorectal adenocarcinoma, and
pituitary adenomas [24-27]. Serum circulating CCNB2
mRNA levels were found to be higher in lung and digest-
ive tract cancer patients compared to normal controls and
were correlated with cancer stage and metastasis status
[28]. Furthermore, the CCNB2 gene was included in the
set of genes detected in node-negative breast tumors asso-
ciated with poor prognosis [29]. Our results suggest that
CCNB2 has an oncogenic potential and its overexpression
may give some proliferative advantage. We have shown a
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breast tumor type, indicating that the CCNB2 protein
levels were unevenly distributed among the histological
types. Notably, no statistically significant differences were
identified between CCNB2 protein levels in relation to pa-
tient age, tumor size, tumor grade, ER/PR status, HER2/
neu, stage, and axillary lymph node status. However, a dis-
similar trend has been reported in serum circulating
CCNB2 mRNA, since it was found to correlate with both
grade and metastasis status [28]. The multivariate analysis
including CCNB2 and several clinicopathological para-
meters further verified that CCNB2 remained an inde-
pendent prognostic indicator for DSS. These data indicate
that tumors with histological grade (I, II and III), axillary
lymph node status (positive, negative), tumor size (0–2,
2–5, and >5), ER/PR status (positive, negative) and HER2/
neu status, exhibiting CCNB2 protein expression, have a
more unfavorable prognosis, with an increased risk of over-
all shorter survival rates. Moreover, the predictive power of
CCNB2 in addition to the clinicopathological parameters
model was slightly higher compared to the lower C-index
of the model including all clinicopathological parameters
alone. Thus, the accuracy in patient prognosis may be
improved by measuring CCNB2 expression in cases of
breast cancer.
The ASPM protein was reported to participate in spin-
dle organization, spindle orientation, mitotic progression,
and cytokinesis [10,11,30,31]. Furthermore, the ASPM
protein is over-expressed in various cancers [10,32-35]
and its knockdown inhibits tumor proliferation [32].
There was no association between elevated ASPM protein
levels and DSS or any other clinical parameters, suggesting
that ASPM may be involved only in cancer initiation. A
significant correlation between CCNB2 and ASPM was
observed. The induction of ASPM and CCNB2 has previ-
ously been reported to regulate the G2/M cell cycle pro-
gression [36]. Thus, elevated levels of CCNB2 may reflect
a functional correlation with ASPM overexpression, which
could play a role in the progression of breast carcinoma.
Furthermore, up-regulation of CCNB2 and ASPM was
detected in glioblastoma multiforme xenograft tumors
and de novo glioblastoma multiforme tumors [37]. Activa-
tion of CCNB2 and ASPM genes induces tumorigenic phe-
notypes in a number of cancers, whereas their inhibition
abrogates cellular proliferation in mice and induces gen-
omic instability [23,38].
The CDCA7 gene has been implicated in neoplastic
transformation and it is one of the downstream targets of
the Myc oncogene [13]. Interestingly, high nuclear expres-
sion of CDCA7 was seen in all the analyzed tumors in the
present study. It is known that deregulation of cell cycle
control is a fundamental feature of cancer pathogenesis,
therefore it was not unexpected that CDCA7 protein has
been observed to be expressed at high levels in almost all
selected tumors. KIAA0101 is predominantly expressed in
mitochondria and partially in nuclei, playing an essential
role in the regulation of DNA repair, cell cycle progres-
sion, and cell proliferation [12]. Moreover, the KIAA0101
gene is over-expressed in tumors of the esophagus [39],
colon [40], lungs [41,42], and breast [43]. KIAA0101-
positivity was observed in 79% of the immunostained
tumors. Up-regulation of KIAA0101 was confirmed by
real time qRT-PCR, which showed the over-expression of
the gene at the mRNA level in 92% of the studied tumors.
The possibility of tissue heterogeneity, accounting for the
discordance between mRNA and protein expression can-
not be excluded. In addition, there was no association be-
tween elevated CDCA7 and KIAA0101 protein levels and
DSS or any other clinical parameters. The CDCA7, and
KIAA0101 may therefore only have role in tumor initi-
ation. Discordant results were detected between mRNA
and protein expression of SLC27A2. High mRNA expres-
sion was detected in 83% of the analyzed tumors, but pro-
tein expression was only seen in 25%, possibly owing to
posttranscriptional regulation and differences in mRNA,
and protein turnover rates or poor specificity of the anti-
body used for IHC [44,45]. These findings suggest that
down-regulation of SLC27A2 in the selected tissues at the
protein level may contribute to disease progression. In-
deed, this gene was reported to regulate the tumor sup-
pressor gene PARP and decreased SLC27A2 expression
levels were found in the metastatic compared to the non-
metastatic neuroendocrine tumors [46]. However, no sig-
nificant difference could be seen on the effect of SLC27A2
protein expression on DSS in breast cancer, nor could any
association between the protein expression of SLC27A2
and the conventional clinical characteristics be observed.
To our knowledge, this is the first study in breast cancer
patients reporting CCNB2 a sap r o g n o s t i cm a r k e rf o ru n -
favorable patient prognosis. Since several publications
revealed that altered CCNB2 expression is seen in many
cancer types, therefore further investigation to elucidate
the mechanism by which CCNB2 exerts its effects may
prove useful in the development of novel anticancer agents.
Conclusions
In summary, we report here that CCNB2 expression
represents a threshold that can stratify breast cancer
patients in a high risk group associated with an increased
probability of mortality when compared to 8-year survi-
vors. Moreover, our data suggests that CCNB2 is a poten-
tial independent prognostic factor and may be useful in
conjunction with other clinicopathological features in
breast cancer.
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